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a b s t r a c t
Background: The natural history of depression in stroke patients is complex and the mechanism of
change in symptoms over time is not fully understood. We hypothesise that there are different trajec-
tories of symptoms after stroke.
Methods: The primary analysis comprised 761 patients who completed 5 years follow up, obtained from
the prospective South London Stroke Register (1998–2013). The Hospital Anxiety and Depression scale
(HADs) was used to screen patients for depression symptoms at 3 months after stroke, then annually.
Trajectories of depression symptoms were detected using group based trajectory modelling (GBTM).
Results: Four patterns of symptoms (Groups I–IV) were identiﬁed: 6.31% of patients had severe symp-
toms, improved slightly in early years then worsen (predicted mean HADs score, 15.74 (se¼1.06));
28.65% had moderate symptoms, a tendency to get worse over time, predicted mean score 7.36
(se¼0.35); 49.54% had mild symptoms and a tendency of getting worse, predicted mean 3.89 (se¼0.30),
and 15.51% of the cohort, had no symptoms and remained so over time. The lowest rate of Selective
serotonin reuptake inhibitors (SSRI) use, over 5 years after stroke was 1.1% for group (I) and highest was
35% for group (IV). Sensitivity analyses were used to assess the robustness of the ﬁndings using several
inclusion criteria and ﬁndings agreed with the primary results.
Limitations: There is loss to follow up of around 20%.
Conclusions: The study identiﬁed 4 trajectories of depression symptoms, providing useful information for
the long term management of stroke patients and for the implementation of cost effective personalized
interventions.
& 2016 Elsevier B.V. All rights reserved.
1. Introduction
Systematic reviews and meta-analysis have recently estimated
that depression prevalence at any time point up to 15 years after
stroke is around 30%.(Ayerbe et al., 2013b; Hackett and Pickles,
2014) Depression is associated with disability, poor quality of life,
increased mortality, and slow recovery (Lai et al., 2002; Robinson,
2003).
The pattern of depression development over time is not fully
understood in stroke patients. Evidence is patchy and
controversial, often suggesting decreasing incidence rates (Aben
and Verhey, 2006), increasing (Lincoln et al., 2013) and or dy-
namic, with episodes of recovery and recurrence over time.
(Ayerbe et al., 2013a; Farner et al., 2010; Wade et al., 1987) No
study to our knowledge has either formally examined the het-
erogeneity of developmental patterns over time or used formal
diagnostic criteria to estimate the prevalence rates of different
severity levels of depression long term after stroke and the asso-
ciation of these with disability and socio-demographic factors.
The hypothesis that a single model or developmental pathway
can explain everyone's risk of an outcome or disorder such as
depression may be unrealistic. Conventional growth trajectory
models use a rather simpliﬁed assumption that individuals belong
to a single population and estimate a single average trajectory to
describe development in the entire population (multilevel random
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effect models (Goldstein and Rasbash, 2003)). Group based tra-
jectory models (GBTM)(Nagin and Odgers, 2010b), and Growth
mixture modelling (GMM) (Muthen and Muthen, 2000), are up to
date statistical procedures designed to identify clusters of in-
dividuals (trajectories) who have followed a similar developmental
trajectory of an outcome of interest over time. The methods are
increasingly being applied in clinical research and have helped to
elucidate important associations, including relationships between
different patterns of drug misuse (adolescent-limited versus life
course persistent) and the development of antisocial behaviours;
the identiﬁcation of trajectories of prostate speciﬁc antigen (PSA)
biomarker and the differential development of prostate cancer,
have been used to estimate differences in the prevalence of psy-
chiatric disorders among children with and without intellectual
disabilities and to identify differential psychosocial exposures for
each. (Emerson and Hatton, 2007; Kandel et al., 1992; Mofﬁtt and
Klaus-Grawe Think, 2013; Muthen, 2006; Pearson et al., 1994)
In this study we aim: (I) to establish the presence of different
patterns of development (trajectories) in depression symptoms
long term after stroke, (II) to estimate the prevalence of each, and
to examine associations between different patterns and stroke
severity, physical disability, and the uptake of antidepressants.
2. Methods
2.1. Design
Patients were recruited between 1998 and 2013 from the South
London Stroke Register (SLSR), a prospective population-based
cohort study, and were followed up to June 2014. The World
Health Organization (WHO) deﬁnition of stroke was used (Hatano,
1976). To increase the completeness of notiﬁcation sixteen over-
lapping referral sources were used (Heuschmann et al., 2008). The
STROBE ﬂowchart provides details (Fig. 1). Some of the patients
who were lost to follow at 3 months were captured at a later time
points. Data collected during the acute phase of stroke included
socio-demographic factors, medication use, comorbidities and
stroke severity, including Glasgow coma scale (GCS) scores (cate-
gorized as severe (3–8), moderate (9–12), and mild (13–15) levels
of impairment), incontinence, and paresis. Patients were assessed
at three months after stroke, one year after stroke and then an-
nually. Follow up at 3 months after stroke was by postal ques-
tionnaire or interview. At follow up patients were screened for
depression using the Hospital Anxiety and Depression scale
(HADs) (Zigmond and Snaith, 1983). HADs comprised 14 items,
7 items screen for depression and 7for anxiety. The scale has been
validated in stroke patients and has shown good performance both
when it is used by an interviewer and when it is self-administered
(Aben et al., 2002). Selective serotonin reuptake inhibitors (SSRI)
use pre-stroke, at 3 months, and annually after stroke was re-
ported. As a UK study, we have focused on the use of SSRI only, as
these were the most commonly used, well deﬁned as a group, and
they cause fewer side effects, according to evidence from the NHS
and the National Institute for Health and Care Excellence (NHS,
2015; NICE, 2015).
Patients with impaired communication were not assessed by
HADs. Disability was assessed at the acute phase, and at follow up,
using the Barthel Index (BI) (Mahoney and Barthel, 1965) cate-
gorised as severe disability (0–14); moderate (15–19) and in-
dependent (20). The scale was validated for use in stroke patients
and was reported to have excellent reliability (Duffy et al., 2013;
Wolfe et al., 1991). Primary and sensitivity analyses were per-
formed using different inclusion criteria.
Fig. 1. Flow chart showing the number of stroke patients included at each follow-
up (APA, 2000). [Legend: n¼number of patients interviewed; LTF¼Lost to follow
up; FU¼completed the follow up; HAD¼HAD completed].
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2.2. Primary analysis inclusion criteria
The primary analysis was conﬁned to patients who had their
ﬁrst-ever stroke before 2009, have complete 5 years of follow up,
and have completed the HADs in at least 4 occasions (n¼761). The
purpose was to ensure a large sample, with reasonably long term
follow up, and with good completion rate of HADs.
2.3. Sensitivity analyses inclusion criteria
The criteria used were: (a) patients with 4 or more measure-
ments of HADs between 3 months to 5 years after stroke,
(n¼852); (b) patients with 7or more measurement of HADs be-
tween 3 months to 10 years after stroke (n¼613); (c) patients with
8 or more measurements of HADs between 3 months to 15 years
after stroke (n¼350), and (d) patients with 4 or more measure-
ments of HADs during the 15 years follow up (n¼1061).
These analyses were performed for two reasons: (1) to assess
the robustness of the results from the primary analysis using dif-
ferent lengths of follow up times and different numbers of ob-
servations per participant, and (2) to examine the impact of im-
portant time varying and time invariant covariates including an-
xiety, the use of antidepressants, gender and age at stroke onset,
on the shapes and the membership of the trajectories obtained by
the primary analysis.
2.4. Statistical analysis
The study conformed to the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) recommenda-
tions (von Elm et al., 2007). Chi squared test was used to compare
proportions for categorical variables and the Analysis of Variance
(ANOVA) and Kruskal-Wallis were used for continuous variables. P
valuer0.05 was used as a criterion for signiﬁcance.
The probability that a subject belongs to a latent class (trajec-
tory), with each class representing a sub-population was modelled
using the censored normal (Tobit) model. The model was re-
commended for the analysis of repeated measurements of con-
tinuous scores such as HADs’ (Nagin and Odgers, 2010a). HADs
depression scores over time were used as continuous outcome.
The software developed by Jones and Nagin, for the analysis of
GBTM was installed in Stata and the command “traj” was used
(Jones, 2013). The model has the capability to adjust for the effect
of time varying or time invariant covariates on the probability of
group membership and on the shape of the trajectories (Nagin,
2005). We used these features in a sensitivity analysis to examine
the effect of time varying factors: anxiety and antidepressant use,
and the time invariant: gender, and age at stroke onset, on the
shape of development over time and on the patients’ membership
to trajectories.
A range of (1–8) trajectories were examined, and shapes that
range between 1st and 3rd order polynomial functions of time
since stroke for each trajectory, were speciﬁed and tested. Three
different considerations were used to decide on the number and
shapes of the selected trajectories: (1) the Bayesian information
Criterion (BIC) statistics, a low BIC indicates well-ﬁtting model;
(2) the classiﬁcation quality using the posterior probabilities: the
average posterior probability for the assignment of individuals to a
class should be considerably higher than the average posterior
probabilities for the assignment of these individuals to other
classes, and (3) the meaning of the classiﬁcation, judging the si-
milarity and differences between trajectories, the size of each, and
the usefulness in practice. (Muthen and Muthen, 2000; Nagin and
Odgers, 2010b)
The socio-demographic characteristics, stroke severity and an-
tidepressants use for the ﬁnal groups deﬁned by the primary
analysis were estimated. Groups were compared in selected
characteristics only, for example, the proportion with severe
physical function limitations, due to the large number of possible
comparisons, and the resulting inﬂation of Type I error. The soft-
ware Stata (Version 13) (StataCorp., (2013). Stata Statistical Soft-
ware: Release 13. College Station) was used for all analyses.
3. Results
3.1. Summary of main features of the register data
The STROBE ﬂowchart provides details of patients recruited
between 1998 and 2013 follow up data (Fig. 1). Appendix 1
(Supplementary), provides a summary comparison of the demo-
graphy and stroke severity of patients who died, lost to follow at
3 months, and those who completed the 3 month's assessments.
Brieﬂy, patients who died have more severe stroke, and were
about 10 years older (mean age 74.8; SD¼14.5) than those fol-
lowed, or lost to follow. Patients who were lost to follow, are
slightly younger than those who were followed, mean age (66.29;
SD¼15.89) and (69.59; SD¼13.63), for the two groups respec-
tively. Comparisons with respect to other factors did not show
appreciable differences. It is however, inappropriate to make
conclusions about differences, due to the large proportions of
missing data in the patients who were lost to follow.
3.2. Primary analysis results
The primary analysis comprised 761 patients, identiﬁed 4 de-
velopmental trajectories of depression symptoms. Estimates of the
parameters of these were displayed in Table 1. The ﬁrst trajectory
(Group I) represents patients with no depression symptoms
(15.51%) who remain so over time (polynomial type: constant);
Group II, includes patients with mild symptoms (49.54%), and a
tendency for a slight increase in symptoms over time (polynomial
type: positive linear); Group III, has patients with moderate
symptoms (28.65%), and a stronger tendency for deterioration over
time (polynomial type: positive linear), and Group IV has patients
with severe symptoms (6.31%), a tendency for a signiﬁcant de-
crease, followed by an increase (polynomial type: linear and
quadratic).
The censored Tobit model ﬁts the data well and the four tra-
jectories’ solution was taken as best solution using the criteria
described in methods, including the Bayesian information criter-
ion (BIC), Akaike information criterion (AIC), group membership
Table 1
Estimates of 4 trajectories of depression from 3 months to 5 years after stroke.
Group Parameter Estimate Standard Error P value
I Intercept 1.18 0.38 o0.001
Intercept 3.89 0.30 o0.001
II Linear 0.14 0.05 0.01
III Intercept 7.36 0.35 o0.001
Linear 0.24 0.07 o0.001
IV Intercept 15.74 1.06 o0.001
Linear 1.79 0.67 0.01
Quadratic 0.24 0.09 0.01
n % (95% CI)
I 118 15.51% 13.10% 18.26%
II 377 49.54% 45.99% 53.10%
III 218 28.65% 25.54% 31.97%
IV 48 6.31% 4.78% 8.28%
Total 761
Note. Group I–IV stand for patients within the 4 trajectories of depression identiﬁed
in the primary analysis.
S.A. Ayis et al. / Journal of Affective Disorders 194 (2016) 65–71 67
probabilities, and the meaningful and sizes of the groups. Al-
though BIC was lowest for a 5 groups' solution, the addition of a
5th group only decreases the BIC slightly, and created an inter-
mediate group between groups I and II, including patients with
mild symptoms, and with characteristics between those for groups
I and II which was not considered a meaningful addition. The BIC
and AIC followed a fairly similar patterns over the 8 models ex-
amined. The BIC and AIC corresponding to1–8 trajectories ex-
amined were given by supplementary Fig. S1.
The average posterior probabilities of assignment to groups
were very high for members assigned to each group, compared to
the probabilities of these being assigned to other groups (Table 2).
The highest average posterior probability was 0.938, for the as-
signment of members to Group IV, and the lowest was 0.832
(considered fairly high) was the average probability for the as-
signment of members to Group I.
Table 3, summarizes the demography, and measures of stroke
severity in the acute phase, including paresis, GCS, incontinence,
and physical function for the four groups. The table shows that
Group I, has younger patients than Groups II and III, has marked
majority of males (66.10%), less severe stroke, and the lowest
proportion of severe physical function limitations (17.80%) in the
acute phase, compared to 26.3%, 33.9% and 35.4%, for the groups
II–IV respectively. The group with severe depression symptoms
(Group IV) has higher rates of impairments, paresis, and physical
function limitations, compared to the other groups. The two in-
termediate groups (II and III) have signiﬁcantly higher proportions
of males, and of older patients compared to Group IV. The ethnic
structure also differs across groups, notably Groups II and III have
higher proportions of Blacks compared to others.
The physical function status and use of SSRI, between 3 months
and 5 years after stroke for the 4 groups (I–IV) are presented in
Table 4. Throughout the 5 years of follow up, Group I, and Group II,
showed consistently better physical function than the other
groups. Differences across groups were signiﬁcant (p
valueo0.001). Group I, has over 70% of fully independent patients
up to 3 years, and over 60% of those, up to 5 years after stroke. The
proportions of fully independent patients decreased over time and
were remarkably small for Group IV. Antidepressants’ (SSRI) use
pre stroke was low in all groups, and the difference was not sig-
niﬁcant at the 5% level. Post stroke use differ across groups
throughout the 5 years, and the differences were signiﬁcant (p
valueo0.001). SSRI use was consistent with depression symp-
toms, with lowest rates of use being observed in group I, and
highest rates in group IV, with highest proportion observed being
35%.
The 4 trajectories of the primary analysis were graphically
presented along with the observed mean HADs' scores, at each
follow up time in Fig. 2. No differences were noted between the
observed means and medians of the scores over the 5 years follow
up. The means were presented to illustrate the agreement be-
tween the observed and predicted means, as the Tobit model is
based on prediction of means. The observed means in panel
(a) and the predicted means in panel (b) were in good agreement
over the 5 years and for the 4 trajectories (I–IV).
3.3. Sensitivity analyses results
The estimates of the 4 trajectories based on inclusion criteria
(a) and (b), were presented in Appendix 2, and those based on
inclusion criteria (c) and (d), in Appendix 3. The numbers and
shapes of the primary analysis trajectories were maintained for all
data sets. For (d) however, the quadratic term was not signiﬁcant
in the sensitivity analysis; removing the quadratic term, did not
alter groups’ membership.
The agreements between the groups derived from the primary
analysis using a strict criterion and those based on other larger and
smaller samples using different criteria (a–d) were high. Kappa
values range between 0.67(se¼0.04) and 0.97(se¼0.02) and
weighted Kappa between 0.86(se¼0.04) and 0.99(se¼0.04). Ad-
justment for the covariates did not alter the signiﬁcance of any of
the shape parameters, and the effect on membership probabilities
was negligible (not presented).
Table 2
Mean posterior probabilities of assignment of groups (I–IV) for members of each
group
Mean SD Min Max
Group
I 0.832 0.152 0.500 0.999
II 0.086 0.121 0.000 0.489
III 0.000 0.000 0.000 0.000
IV 0.000 0.000 0.000 0.000
Group II
I 0.168 0.152 0.000 0.500
II 0.836 0.128 0.502 0.985
III 0.093 0.128 0.000 0.496
IV 0.000 0.000 0.000 0.000
Group III
I 0.000 0.000 0.000 0.000
II 0.078 0.121 0.000 0.497
III 0.873 0.138 0.502 0.998
IV 0.062 0.114 0.000 0.495
Group IV
I 0.000 0.000 0.000 0.000
II 0.000 0.000 0.000 0.000
III 0.034 0.094 0.00 0.497
IV 0.938 0.114 0.505 0.999
Note. SD: Standard deviation. 0.000 indicates very small values, approximated to
the nearest 3 decimal places.
Table 3
Demography and stroke severity in the acute phase for four groups of patients.
Group I II III IV Total
Group size (n) 118 377 218 48 761
Mean age 62.02 66.20 64.38 60.59 64.67
(SD) 13.36 13.09 12.96 10.75 (13.06)
Sex
Male 66.10% 55.40% 54.10% 47.90% 56.20%
Female 33.90% 44.60% 45.90% 52.10% 43.80%
Ethnicity
White 72.00% 68.20% 66.10% 72.90% 68.50%
Black 22.00% 24.70% 29.40% 12.50% 24.80%
Others 4.20% 5.60% 3.70% 14.60% 5.40%
Unknown 1.70% 1.60% 0.90% 0.00% 1.30%
Paresis
No 50.00% 30.20% 17.00% 20.80% 28.90%
Yes 39.80% 57.60% 67.00% 62.50% 57.80%
Unknown 0.80% 0.80% 0.90% 0.00% 0.80%
Incontinence
No 89.80% 78.50% 71.60% 81.30% 78.40%
Yes 6.80% 19.40% 24.80% 14.60% 18.70%
Unknown 3.40% 2.10% 3.70% 4.20% 2.90%
Glasgow Coma Scale (GCS)
Severe 2.70% 1.60% 3.30% 2.10% 2.30%
Moderate 2.70% 6.50% 8.60% 4.30% 6.40%
Mild 94.70% 91.80% 88.10% 93.60% 91.30%
Barthel Index (BI) at the cute phase
Severe limitations (0–14) 17.80% 26.30% 33.90% 35.40% 27.70%
Moderate limitations (15–19) 12.70% 18.60% 18.80% 20.80% 17.90%
Independent (20) 55.90% 36.10% 27.50% 27.10% 36.10%
Unknown 13.60% 19.10% 19.70% 16.70% 18.30%
Note. Group I–IV stand for patients within the 4 trajectories of depression identiﬁed
in the primary analysis.
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4. Discussion
The study identiﬁed 4 groups of stroke patients with remark-
able differences in the mechanisms of the development of de-
pression symptoms over time providing further insight into the
natural history of depression after stroke. The groups include pa-
tients with severe symptoms (6.31%) that may decrease slightly at
early years before getting worse again, moderate (28.65%) and
mild symptoms (49.54%) that increase over time, and patients who
were free of depression symptoms (15.51%), and remain so over
time.
Estimates on the prevalence of depression after stroke, varied
considerably across studies. A pooled estimate of 31% (95% CI: 28%
to 35%) in stroke survivors at any time up to 5 years after stroke,
has been reported in a recent systematic review including 61
studies (Hackett and Pickles, 2014). Our ﬁndings supplement
current knowledge on overall prevalence, by providing details on
different levels of symptoms and varying patterns of development
over time. Awareness of the presence of such a range of prognosis
with different needs represents additional and timely evidence
that is currently needed for the effective and cost effective appli-
cations of stratiﬁed medicine. It may also be useful for the ap-
propriate assignment of patients to interventions in clinical trials.
Researchers and clinicians have widely acknowledged that
depression needs clinical attention in the long term but the poor
prognosis of vulnerable patients makes long term interventions
difﬁcult to develop and to deliver (McKevitt et al., 2011; Wolfe
et al., 2011). A better understanding of the long term development
is necessary for the implementation of effective strategies for re-
habilitation and long term management. Our results suggest the
need for clinicians to consider differences in the development of
depression symptoms in stroke patients, acknowledging that pa-
tients with moderate and severe symptoms are at high risk for
remaining depressed or even getting worse. The signiﬁcant risk of
increase in mild symptoms noted soon after stroke in 49.54% of
patients, also suggest the need for periodic clinical attention in the
long term to be considered for appropriate management.
While 5 years follow up was chosen for the primary analysis as
short enough for a large number of patients to be still alive and to
contribute data at several occasions, the sensitivity analyses have
covered 10, and 15 years of follow up, and the 4 group structure
remained.
The use of GMM and GBTM methods is increasing and recent
applications have strengthened the evidence on their value.
Through better understanding of patients' heterogeneity the
methods allowed the discovery of differential patterns in the
progress of biomarkers, behavioural disorders, response to inter-
ventions, and recovery patterns (Brown et al., 2008; Haviland
et al., 2007; Lin et al., 2000; Peer and Spaulding, 2007).
To our knowledge no large scale quantitative study has at-
tempted to describe trajectories of depression symptoms after
stroke. A qualitative study however, has closely followed up 23
stroke patients for 12 months after stroke and has identiﬁed
4 trajectories of psychological distress (White et al., 2012). Al-
though the two studies differ in methodology, follow up time,
scales used, the focus being on disturbed mood rather than de-
pression symptoms in the earlier study, but nonetheless, there are
similarities in the developmental features of symptoms that are
highly related, in the two studies, and in particular for two groups.
The ﬁrst group, deﬁned as “Resilient”, where patients remain in a
stable good mood throughout 12 months follow up, resembles,
Group I, identiﬁed in our study. This may be interpreted that some
patients continue to have no depression symptoms long term after
stroke. In addition our study has shown that majority of this group
were males, fully independent and have maintained physical
function independence long term after stroke. The second group,
described as “on going mood disturbance trajectory” comprising
patients with ongoing feelings of difﬁculty that continued and
exacerbated over time, bears fair similarity to Groups III and IV
deﬁned in our study, suggesting that features of severe psycho-
logical problems reported for 5 patients over 12 months after
stroke, may persist 5 years or longer and the prevalence of these is
high (over 30%) in stroke patients.
Researchers have reported contradicting associations with an-
tidepressants' use, including positive ones such as improved
physical function, and negative such as the increased risk of stroke
and mortality, and have questioned the long term safety, the
clarity and availability of guidelines for their optimal use (Ayerbe
et al., 2014; Coupland et al., 2011; Hackett et al., 2008; Rayner
et al., 2011). Our study has shown that these medications were
used by between, 21% and 35% of patients with severe symptoms
over 5 years after stroke, and rates decreases consistently with
milder symptoms. For appropriate interpretation of these esti-
mates however, data on compliance, safety, and guidelines for long
term use that were reportedly patchy or unavailable would be
necessary.
The strengths of this study included the use of long term follow
up data derived from an established, prospective, population
based stroke register, with 88% of incidents stoke occurring in the
study area being registered, as reported by a capture recapture
analysis (Tilling et al., 2001); a completion rate of HADs of over
Table 4
Physical limitations and antidepressants (SSRI) use before and 5 years after stroke
for groups (I–IV) of patients.
Group I II III IV Total
Size (n) 118 377 218 48 761
BI at 3 months after stroke
Severe limitations (0–14) 0.00% 6.10% 18.80% 29.20% 10.20%
Moderate limitations (15–19) 15.30% 27.60% 36.70% 31.30% 28.50%
Independent (20) 60.20% 41.10% 22.00% 14.60% 36.90%
Unknown 24.60% 25.20% 22.50% 25.00% 24.30%
BI at 1 Year
Severe limitations (0–14) 0.00% 5.60% 19.30% 25.00% 9.90%
Moderate limitations (15–19) 14.40% 36.60% 37.60% 31.30% 33.10%
Independent (20) 78.00% 48.80% 33.50% 25.00% 47.40%
Unknown 7.60% 9.00% 9.60% 18.80% 9.60%
BI at 2 Years
Severe limitations (0–14) 0.00% 8.20% 18.30% 16.70% 10.40%
Moderate limitations (15–19) 20.30% 35.00% 41.30% 56.30% 35.90%
Independent (20) 71.20% 48.30% 27.10% 10.40% 43.40%
Unknown 8.50% 8.50% 13.30% 16.70% 10.40%
BI at 3Years
Severe limitations (0–14) 1.70% 9.00% 19.70% 33.30% 12.50%
Moderate limitations (15–19) 13.60% 35.50% 44.50% 39.60% 35.00%
Independent (20) 74.60% 46.90% 24.80% 14.60% 42.80%
Unknown 10.20% 8.50% 11.00% 12.50% 9.70%
BI at 4 Years
Severe limitations (0–14) 0.80% 7.40% 27.50% 29.20% 13.50%
Moderate limitations (15–19) 17.80% 38.50% 39.90% 35.40% 35.50%
Independent (20) 66.10% 41.40% 19.70% 14.60% 37.30%
Unknown 15.30% 12.70% 12.80% 20.80% 13.70%
BI at 5 Years
Severe limitations (0–14) 1.70% 9.80% 23.40% 33.30% 13.90%
Moderate limitations (15–19) 14.40% 31.30% 31.20% 25.00% 28.30%
Independent (20) 62.70% 32.40% 15.60% 14.60% 31.10%
Unknown 21.20% 26.50% 29.80% 27.10% 26.70%
Antidepressants (SSRI) use
Pre stroke 0.80% 2.70% 3.70% 6.30% 2.90%
3 months after stroke 1.10% 4.20% 16.00% 23.70% 8.40%
1 year 3.70% 5.20% 12.40% 32.50% 8.60%
2 years 1.80% 4.60% 16.80% 35.00% 9.30%
3 years 1.80% 5.90% 19.40% 26.70% 10.40%
4 years 2.80% 6.70% 18.40% 21.40% 10.40%
5 years after stroke 2.00% 7.50% 20.70% 24.30% 11.40%
Note. SSRI stands for 5 selective serotonin reuptake inhibitors; BI: Barthel Index.
Overall (P values) for all comparisons across groups were o0.001, except p-value
for the comparison of pre stroke SSRI use (P value¼0.86).
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75%, and up to 87%; the use of GBTM to deﬁne subgroups of dif-
ferent developmental patterns of depression based on formal
statistical methodology that provide the necessary tools to dis-
tinguish real from random variations in behaviour, such distinction
is not possible using ad-hoc classiﬁcation; the models allow the
recognition of the HADs scores as continuous measures overcoming
the difﬁculty of choice of best threshold, as there is no full agree-
ment across studies on that and ﬁndings from systematic reviews
have shown a wide range (4–11) of cut off points being used.
On the limitation side however, there is loss to follow up of
around 20% on average, and women have slightly higher rates of
loss to follow up compared to men. Part of the missing data were
due to the inability of some patients with cognitive or commu-
nication impairment to respond to the HADs. While this may in-
troduce bias, estimates in the main baseline characteristics from
patients with complete data showed no signiﬁcant differences
from those lost to follow up. A method's related limitation is that
the existence of sub-groups must be assumed a priori (Nagin and
Odgers, 2010b). Assessing depression with a screening scale may
represent a limitation, however, although HADs was originally
developed as a screening tool for anxiety and depression in hos-
pital patients, it has been validated for use in stroke patients and
in the general population (Aben et al., 2002). A recent meta-ana-
lysis has shown an optimum performance of HADS' depression, for
identifying any depression with 0.85 (95% CI: 0.78–0.91) sensi-
tivity, and 0.69 (95% CI: 0.60–0.76) speciﬁcity, and for identifying
severe depression with 0.82 (95% CI: 0.70–0.90) sensitivity, and
0.76 (95% CI: 0.72–0.80) speciﬁcity (Meader et al., 2014) where the
reference standard was diagnosis according to DSM or ICD criteria
(World Health Organization., 1993; APA, 2000).
Finally despite the good agreement in the number and shapes of
trajectories based on different assumptions, and different samples
internally using sensitivity analysis, there remains the need to ex-
ternally validate these trajectories using independent data sets.
In summary, this study has identiﬁed for the ﬁrst time 4 sub-
groups of patients with varying levels of depression symptoms and
with distinct mechanisms of change in symptoms over time, fur-
thering knowledge for better understanding of the natural history
of depression after stroke. The study estimated the prevalence of
different levels of severity in depression symptoms and the rates
of antidepressants use by each. Awareness of patients with dif-
ferent prognosis represents an additional knowledge that is useful
for the implementation of personalized interventions and for the
appropriate stratiﬁcation of patients in clinical trials.
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